A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.
Video Player is loading.
Play Video
Play
Mute
Current Time 0:00
/
Duration 0:00
Loaded: 0%
0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -0:00
1x
Playback Rate
2x
1.75x
1.5x
1.25x
1x, selected
0.75x
0.5x
Chapters
Chapters
Descriptions
descriptions off, selected
Captions
captions settings, opens captions settings dialog
captions off, selected
Audio Track
Fullscreen
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
Reset restore all settings to the default valuesDone
Close Modal Dialog
End of dialog window.
Close Modal Dialog
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.